Juvenile hemangiomas (JG) - the most common tumor of childhood, which is estimated by various investigators found in 3-10% of newborns resulting from the local development of significant violations of neoangiogenesis regulation. A new approach in the pharmacotherapy of juvenile hemangiomas (JG) is based on the efficacy of beta-adrenoblocker (β-AB), and the local therapy of juvenile hemangiomas (JG) by beta – adrenoblocker (β-AB) is the most topical method of treatment of focal superficial

more »

... iomas. Understanding of the mechanism of antiangiogenic effect of β-AB is important for widespread use in the treatment of children with juvenile hemangiomas (JG). Given the significant hyperproliferative growth patterns, variability of cytoarchitectonic juvenile hemangiomas (JG) and prerequisites for external application of beta-adrenoblocker (β-AB), performed a study of the influence of timolol on active migration in vitro cell cultures in three lines: HDMEC - culture of endothelial cells, HaCat - line keratinocytes, L-929 – сulture of fibroblasts, chemotaxis was studied in cultured endothelial cells (HDMEC). Experimental tests in vitro indicate the total absence of negative influence on the viability of timolol, mobility and migration of endothelial cells, fibroblasts and keratinocytes. The results of the studies testify to the safety of nonselective beta-adrenoblocker and the absence of a direct negative effect on the cells, which in combination with high efficiency, allows to recommend the use of timolol for the treatment of focal superficial juvenile hemangiomas.